东诚药业：子公司药品达肝素钠注射液增加规格获批上市

Group 1 - The core point of the article is that Dongcheng Pharmaceutical has received approval for a new specification of its low molecular weight heparin product, dalteparin sodium injection, from the National Medical Products Administration [1] - The newly approved specification is 0.2ml: 5000AXaIU, which expands the product's market offerings [1] - Dalteparin sodium injection is primarily used for the treatment of acute deep vein thrombosis, highlighting its significance in the therapeutic area of anticoagulation [1]